-
CSCO 2024 | Dr. Baorui Liu: “Rapid Advancements in Gastric Cancer Treatment, A Bright Future for Young Scholars”
The 27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting was held in Xiamen from September 25 to 29, 2024. This year’s theme, “Patient-Centered, Future-Sharing,” brought together major research advancements and developments from around the world. A dedicated gastric cancer session was organized, gathering top experts in the field to explore the latest progress,…
-
Dr. Jidong Jia Discusses the Establishment of the World Association of Chinese Doctors Physicians Hepatology Committee
Hepatology Digest: The World Association of Chinese Doctors Physicians was established on September 21, 2014, in Macau. It has now been ten years. What historical background and current conditions led…
-
ETER100 Study Showcased at ESMO Late-Breaking Abstract Session: Dr. Xinan Sheng Shares New Advances in Targeted and Immunotherapy
Renal cell carcinoma (RCC) is one of the most common malignancies of the urinary system. In recent years, the exploration of combined immunotherapy strategies in RCC has transformed the treatment landscape, making immuno-targeted therapy the global first-line standard for advanced renal cancer. The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in…
-
CUA 2024丨Dr. Xin Yao: ADC Leading the Era of Combined Targeted and Immunotherapy for Advanced Urothelial Cancer
For many years, platinum-based chemotherapy has been the cornerstone of systemic treatment for advanced urothelial cancer, such as bladder cancer. However, the release of clinical research data on antibody-drug conjugates (ADC), such as enfortumab vedotin (EV), has brought new treatment options for patients. During the 31st Urology Academic Conference held recently in Tianjin, Dr. Xin…
-
Dr. Hao Zeng Shares the West China Hospital Team’s Experience in Treating Special Types of Renal Cancer and Clinical Exploration
Renal cancer is one of the three major tumors of the urinary system. Several large phase III studies on combined targeted and immunotherapy have been successful, and the 2024 update of the CSCO renal cancer diagnosis and treatment guidelines has officially brought first-line treatment for advanced renal cancer into the era of combined targeted and…
-
Interview with Dr. Swaminathan P iyer at the EHA 2024: Exploring Breakthroughs in Secondary HLH Treatment with ELA26
At this year’s European Hematology Association (EHA) conference, we had the opportunity to speak with Dr. Swaminathan P iyer, Professor of Medicine at MD Anderson Cancer Center, about the groundbreaking phase I study on ELA26 for secondary hemophagocytic lymphohistiocytosis (HLH). Dr. Iyer shared the promising data from the treatment-naive cohort, which showed a remarkable 100%…
-
-
ESMO 2024丨Dr. Silke Gillessen: Radium-223 Combined with Enzalutamide Offers New Hope for Bone Metastatic mCRPC Patients
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13 to 17 in Barcelona, Spain. Key research in the field of urologic oncology garnered much attention, particularly in the area of prostate cancer. The EORTC-GUCG 1333/PEACE-3 clinical trial (LBA1 – A randomized multicenter open label phase III trial comparing enzalutamide…
Connecting Medical Expertise through Media